What is Idiopathic Pulmonary Fibrosis Market?
Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that results in scarring (fibrosis) of the lungs over time results in reduced oxygen intake for an unknown reason. The symptoms of idiopathic pulmonary fibrosis are non-specific but most patients present with a gradual onset (often >6 mo) of exertional dyspnea and/or nonproductive cough. It is estimated that currently, more than 80,000 adults in the United States have IPF, and more than 30,000 new cases are diagnosed each year. Idiopathic pulmonary fibrosis affects each person differently and the disease progresses at varying rates.
The market study is being classified, by Application (Hospital, Clinic and Others) and major geographies with country level break-up.
MediciNova, Inc. (United States), C.H. Boehringer Sohn AG & Ko. KG (Germany), Roche Holding AG (Switzerland), Merck & Co., Inc. (United States), Baxter International (United States), Prometheus Laboratories Inc. (United States), Afferent Pharmaceuticals, Inc. (United States), Biogen Inc. (United States), Cipla Limited (India) and Bristol-Myers Squibb (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Amgen Inc. (United States) and FibroGen (United States).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Idiopathic Pulmonary Fibrosis market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Idiopathic Pulmonary Fibrosis market by Type, Application and Region.
On the basis of geography, the market of Idiopathic Pulmonary Fibrosis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Idiopathic Pulmonary Fibrosis in Adults
- Rise in the Number of Diagnostic Centres in Developing Countries
- Surge in the Cigarette-Smoking Population
- Advancements in IPF Diagnostic and Treatment Methods
- Lack of Complete Cure Treatment for Idiopathic Pulmonary Fibrosis
- Lack of Healthcare Infrastructure in Under Developed Countries
- Increasing Geriatric Population Worldwide
- Growth in the Healthcare Sector Around the Globe
- Stringent Government Rules and Regulations
In February 2019, Roche and Spark Therapeutics, Inc. has announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics.
Key Target AudienceIdiopathic Pulmonary Fibrosis Drug Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase